These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31090280)

  • 1. Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning.
    Citrome LL; McIntyre RS; Manning JS; McIntosh D
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 31090280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
    Bartova L; Fugger G; Dold M; Kautzky A; Swoboda MMM; Rujescu D; Zohar J; Souery D; Mendlewicz J; Montgomery S; Fabbri C; Serretti A; Kasper S
    Int J Neuropsychopharmacol; 2022 Feb; 25(2):118-127. PubMed ID: 34637516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.
    Al-Dhaher Z; Kapoor S; Saito E; Krakower S; David L; Ake T; Kane JM; Correll CU; Carbon M
    J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):458-70. PubMed ID: 27093218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-Generation Antipsychotic-Induced Hypoglycemia.
    Fujita T; Mizoguchi Y; Kunitake Y; Tateishi H; Inaba T; Kato TA; Monji A
    Prim Care Companion CNS Disord; 2018 Jan; 20(1):. PubMed ID: 29372938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole in refractory depression?
    Carroll BJ
    J Clin Psychopharmacol; 2009 Feb; 29(1):90-1; author reply 92-3. PubMed ID: 19142117
    [No Abstract]   [Full Text] [Related]  

  • 10. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
    [No Abstract]   [Full Text] [Related]  

  • 11. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
    Sussman M; Yu J; Kamat SA; Hartry A; Legacy S; Duffy R; Aigbogun MS
    J Affect Disord; 2017 Jan; 207():54-62. PubMed ID: 27693466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al.
    Tsai AC
    J Clin Psychopharmacol; 2009 Feb; 29(1):91-2; author reply 92-3. PubMed ID: 19142118
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjunctive antipsychotics for major depression.
    Med Lett Drugs Ther; 2011 Sep; 53(1373):74-5. PubMed ID: 21921872
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects.
    DeBattista C; DeBattista K
    Curr Drug Saf; 2010 Jul; 5(3):263-6. PubMed ID: 20394571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
    Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
    Weiss C; Weiller E; Baker RA; Duffy RA; Gwin KK; Zhang P; McQuade RD
    Int Clin Psychopharmacol; 2018 Sep; 33(5):255-260. PubMed ID: 29878915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.
    Aftab A; Gao K
    Expert Opin Drug Discov; 2017 Oct; 12(10):1067-1081. PubMed ID: 28718334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.